TY - JOUR
T1 - Differential expression and release of cd54 induced by cytokines
AU - Mickelson, Judith K.
AU - Kukielka, Gilbert
AU - Bravenec, J. Stanley
AU - Mainolfi, Elizabeth
AU - Rothlein, Robert
AU - Hawkins, Hal K.
AU - Kelly, James H.
AU - Smith, C. Wayne
N1 - Funding Information:
Supported in part by grants from the National Institutes ofH ealth ES06091 (C.W.S.), the American Heart Association Established Investigatorship and Texas Affiliate (J.K.M.), and The Methodist Foundation (G.K.).
PY - 1995/9
Y1 - 1995/9
N2 - Intercellular adhesion molecule-1 (ICAM-1, CD54) is upregulated in many cell types stimulated by cytokines. A human hepatoblastoma cell line (C3A, a subclone of HepG2/C3 that is currently being used as a surrogate liver) and human lung adenocarcinoma cells (A549) were stimulated with interleukin-1β (IL-1β), tumor necrosis factor-α (TNFα), interferon-γ (IFNγ), or IL-6 to determine any differences in cell type responsiveness to individual cytokines for ICAM-1 upregulation. Time courses were performed with each cytokine evaluating ICAM-1 mRNA, surface expression, and cICAM-1 in the cell culture media. Between 3 and 6 hours, IL-1β (30 U/mL) stimulated the greatest increase in hepatocyte ICAM-1 mRNA, followed by IFNγ (100 U/mL), TNFα (30 U/mL), and IL-6 (100 U/mL) in order of potency. Except for IL6, cytokine-induced hepatocyte surface levels of ICAM1 (immunofluorescence flow cytometry, mAb R6.5) were dose dependent, with inhibition at higher concentration. Highest levels followed stimulation with IFNγ (P < .05). Significantly less was found after both IL-1β and TNFa; none was detected after IL-6 (P < .05). In contrast, IL-1β stimulated significantly more cICAM-1 release from hepatocytes than the other cytokines (P < .001), and IL-6 stimulated modest cICAM-1. Between 3 and 6 hours in the A549 cells, IL-1β stimulated the greatest increase in ICAM-1 mRNA, followed by TNFα. Both responses were greater than that observed in the hepatocytes. IFNγ- and IL-6-induced ICAM-1 mRNA synthesis was not different from unstimulated A549 cells. Cytokine-induced A549 surface levels of ICAM-1 (immunofluorescence flow cytometry, mAb R6.5) was highest for IL-1β (peak levels similar to hepatocyte response), modest with TNFα (peak levels less than hepatocytes), detectable with IFNγ (much less than hepatocytes), and nondetectable after IL-6. No cICAM-1 release from A549 cells was induced under any condition. In hepatocytes the amount of ICAM-1 mRNA was best accounted for by considering both cell surface levels of ICAM-1 and cICAM1 levels. In human lung adenocarcinoma cells, the cytokine induction of ICAM-1 mRNA could potentially be accounted for by observing cell surface levels of ICAM1 because no cICAM-1 was produced. These results suggest that surface ICAM-1 and cICAM-1 may be differentially controlled by each cytokine and by each parenchymal cell type.
AB - Intercellular adhesion molecule-1 (ICAM-1, CD54) is upregulated in many cell types stimulated by cytokines. A human hepatoblastoma cell line (C3A, a subclone of HepG2/C3 that is currently being used as a surrogate liver) and human lung adenocarcinoma cells (A549) were stimulated with interleukin-1β (IL-1β), tumor necrosis factor-α (TNFα), interferon-γ (IFNγ), or IL-6 to determine any differences in cell type responsiveness to individual cytokines for ICAM-1 upregulation. Time courses were performed with each cytokine evaluating ICAM-1 mRNA, surface expression, and cICAM-1 in the cell culture media. Between 3 and 6 hours, IL-1β (30 U/mL) stimulated the greatest increase in hepatocyte ICAM-1 mRNA, followed by IFNγ (100 U/mL), TNFα (30 U/mL), and IL-6 (100 U/mL) in order of potency. Except for IL6, cytokine-induced hepatocyte surface levels of ICAM1 (immunofluorescence flow cytometry, mAb R6.5) were dose dependent, with inhibition at higher concentration. Highest levels followed stimulation with IFNγ (P < .05). Significantly less was found after both IL-1β and TNFa; none was detected after IL-6 (P < .05). In contrast, IL-1β stimulated significantly more cICAM-1 release from hepatocytes than the other cytokines (P < .001), and IL-6 stimulated modest cICAM-1. Between 3 and 6 hours in the A549 cells, IL-1β stimulated the greatest increase in ICAM-1 mRNA, followed by TNFα. Both responses were greater than that observed in the hepatocytes. IFNγ- and IL-6-induced ICAM-1 mRNA synthesis was not different from unstimulated A549 cells. Cytokine-induced A549 surface levels of ICAM-1 (immunofluorescence flow cytometry, mAb R6.5) was highest for IL-1β (peak levels similar to hepatocyte response), modest with TNFα (peak levels less than hepatocytes), detectable with IFNγ (much less than hepatocytes), and nondetectable after IL-6. No cICAM-1 release from A549 cells was induced under any condition. In hepatocytes the amount of ICAM-1 mRNA was best accounted for by considering both cell surface levels of ICAM-1 and cICAM1 levels. In human lung adenocarcinoma cells, the cytokine induction of ICAM-1 mRNA could potentially be accounted for by observing cell surface levels of ICAM1 because no cICAM-1 was produced. These results suggest that surface ICAM-1 and cICAM-1 may be differentially controlled by each cytokine and by each parenchymal cell type.
UR - http://www.scopus.com/inward/record.url?scp=0029123479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029123479&partnerID=8YFLogxK
U2 - 10.1016/0270-9139(95)90309-7
DO - 10.1016/0270-9139(95)90309-7
M3 - Article
C2 - 7657294
AN - SCOPUS:0029123479
SN - 0270-9139
VL - 22
SP - 866
EP - 875
JO - Hepatology
JF - Hepatology
IS - 3
ER -